Characteristics of pre-approval efficacy evidence for US accelerated approval and European conditional marketing authorization during 2015-2020ZHANG Xiao-fang, BAI Xue, SUN Wan, WANG Feng-zhi, CHEN Si-yu, WU Yang-feng1-9
Mode research on the technology diffusion in the treatment of neuroblastoma based on patent citationsZHANG Ting, YANG Xiao-yi, CHEN Juan, XU Dong-zi, WANG Ting-ting, OUYANG Zhao-lian10-17
Analysis on drug registration included in the priority review procedure before and after the enactment of the"Drug Registration Regulation"(2020)WANG Shu-fang, TIAN Li-juan18-22
Control strategies for nitrosamine impurities in rifampin and rifapentinDONG Chen-huan, GONG Qing, ZHANG Xin-fang23-27
The discussion on the key points of drug research and development quality management from the perspective of registration inspectionYAN Ruo-xi28-35
Discussion on the inspection method of methanol content in Huoxiang Zhengqi TinctureWU Qiu-ping, XU Yan, NIE Li-xing, CHEN Wei-kang, LIU De-hong, LIU Gui-feng, MA Shuang-cheng36-41
Methodological research and advancements of in vitro permeation test of dermal drug delivery productsMAO Ke-yang, CHONG Xiao-meng, LUO Hua-fei, NING Bao-ming42-54
Research progress of therapeutic drug monitoring of tyrosine kinase inhibitors commonly used in non-small cell lung cancerZHOU Guo-jin, WU Jing-jing, XU Jing, CHEN Jie55-61
Determination of nilotinib in human plasma by LC-MS/MS and its pharmacokinetic studyMA Huan, ZHOU Zhen, LI Zhou, GE Qing-hua, KANG Xiu-yuan62-67
Trilaciclib for prevention of chemotherapy-induced myelosuppression in lung cancer:a case report and literature reviewHUANG Hao-jie, CHEN Tao, XIE Xiao-yuan, CHI Xiu-ying, SUN Jia-ting, CHEN Li-ming68-72